ArticleDiscover oncology2025
Machine learning assists regulated cell death crucial biomarker selection in adenocarcinoma of the lung: biological data testing and cell assay determination.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer is a highly aggressive and lethal cancer requiring prognostic and predictive biomarkers for improving patient outcomes. Here, a prognostic signature for lung cancer was developed and prognostic programmed cell death (PCD)-related genes were identified.
methodsIn this study, we performed comprehensive bioinformatic analyses on diverse datasets, such as Gene Expression Omnibus and The Cancer Genome Atlas. Consensus clustering, Weighted Gene Co-expression Network Analysis, and Gene Set Enrichment Analysis were applied to gain valuable insights from the data, and survival analysis was performed to determine the genes associated with prognosis PCD and construct a prognostic signature.
resultsPCD-related genes (n = 46), significantly correlated with lung cancer prognosis, including ACSL3 and BID, were evaluated. A prognostic gene signature was constructed using 12 genes, which showed excellent overall survival prediction for 1, 3, and 5 years (AUC: 0.687, 0.699, and 0.627). The analysis focused on the nine ley mutant PCD risk model genes and their pan-cancer and elevated mutation frequencies were noted in ALK across several cancer types. The drug sensitivity and immune cell infiltration of the two risk groups were analyzed and revealed noteworthy differences. Patients classified as high-risk demonstrated increased susceptibility to drugs and elevated infiltration of Th2, Tcm, and T helper cells. A prognostic nomogram was developed to predict patient survival at 1, 3, and 5 years, and variables such as age, grading, stage, and the PCD risk score were incorporated. The relationship between PCD-associated genes, genes involved in cell proliferation, and immune cell phenotypes were evaluated. HSPA4 exhibited a significant positive correlation with T helper cells, Th2 cells, and Tcm cells and a negative association with pDCs, TFH, and B cells. In stage III tumors, compared to stage I/II tumors, HSPA4 expression was also significantly upregulated.
conclusionPrognostic PCD-related genes for lung cancer were identified and a prognostic signature was constructed. Our findings are invaluable for lung cancer prognostic prediction and personalized treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.